CAS 2289690-31-7
:Formula:C26H16ClF9N2O2
InChI:InChI=1S/C26H16ClF9N2O2/c1-38-19(11-21(37-38)26(34,35)36)18-6-7-20(40-12-13-2-4-17(27)5-3-13)22(23(18)39)14-8-15(24(28,29)30)10-16(9-14)25(31,32)33/h2-11,39H,12H2,1H3
InChI key:CKLCWLSEYDDTCN-UHFFFAOYSA-N
SMILES:CN1C(=CC(=N1)C(F)(F)F)C2=C(C(=C(C=C2)OCC3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)O
Filtra per
Percentuale di purezza
0
100
|
0
|
50
|
90
|
95
|
100
Trovati 6 prodotti.
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
MYCi361
CAS:MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).Formula:C26H16ClF9N2O2Purezza:99.52%Colore e forma:SolidPeso molecolare:594.866-((4-Chlorobenzyl)Oxy)-3-(1-Methyl-3-(Trifluoromethyl)-1H-Pyrazol-5-Yl)-3',5'-Bis(Trifluoromethyl)-[1,1'-Biphenyl]-2-Ol
CAS:6-((4-Chlorobenzyl)Oxy)-3-(1-Methyl-3-(Trifluoromethyl)-1H-Pyrazol-5-Yl)-3',5'-Bis(Trifluoromethyl)-[1,1'-Biphenyl]-2-OlFormula:C26H16ClF9N2O2Purezza:98%Peso molecolare:594.866-((4-Chlorobenzyl)oxy)-3-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-2-ol
CAS:Formula:C26H16ClF9N2O2Purezza:98%Colore e forma:SolidPeso molecolare:594.85616-((4-Chlorobenzyl)oxy)-3-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-2-ol
CAS:6-((4-Chlorobenzyl)oxy)-3-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-2-olFormula:C26H16ClF9N2O2Purezza:98%Peso molecolare:594.86MYCi361
CAS:MYCi361 is an antibody-drug conjugate that targets the histone deacetylase. MYCi361 has been shown to be effective in treating leukocyte antigen (HLA)-expressing tumours, such as melanoma, colorectal cancer, and breast cancer that overexpress the HER2 receptor. MYCi361 blocks the biological activity of histone deacetylase by binding to it, which results in reduced expression of HLA proteins. This leads to tumor regression and prolonged survival in animal models.
Formula:C26H16ClF9N2O2Purezza:Min. 95%Peso molecolare:594.9 g/mol
